β-Lactamase inhibitors: a review of the patent literature (2010 - 2013). (Q38130715)

29 August 2017

β-Lactamase inhibitors: a review of the patent literature (2010 - 2013). (English)

1 reference

29 August 2017

John D Buynak

1

1 reference

PubMed ID

23967802

29 August 2017

language of work or name

English

0 references

publication date

23 August 2013

1 reference

Expert Opinion on Therapeutic Patents

29 August 2017

1 reference

29 August 2017

23

1 reference

29 August 2017

11

1 reference

29 August 2017

1469-1481

1 reference

Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Is the GAIN Act a turning point in new antibiotic discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Carbapenemases: the versatile beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

OXA-48-like carbapenemases: the phantom menace

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

The spread of CTX-M-type extended-spectrum beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Proliferation and significance of clinically relevant β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

CTX-M: changing the face of ESBLs in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Plasmid-borne AmpC beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Plasmid-determined AmpC-type beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Extended-spectrum cephalosporinases in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Mechanisms of β-lactam resistance among Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Metallo-β-lactamases: a last frontier for β-lactams?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Pseudomonas aeruginosa: all roads lead to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

The rise of carbapenem-resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Methicillin-resistant Staphylococcus aureus in diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Essentials for selecting antimicrobial therapy for intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Reversible inhibitors of penicillinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-Lactamase(,)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Design, Synthesis, Crystal Structures, and Antimicrobial Activity of Sulfonamide Boronic Acids as β-Lactamase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Fragment-guided design of subnanomolar -lactamase inhibitors active in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro and in vivo properties of BAL30376, a β-lactam and dual beta-lactamase inhibitor combination with enhanced activity against Gram-negative Bacilli that express multiple β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Role of beta-lactamase inhibitors in enterobacterial isolates producing extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 2. N-Alkylated and open chain analogs of MK-8712

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

2-Substituted 4,5-dihydrothiazole-4-carboxylic acids are novel inhibitors of metallo-β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.831071

10.1517/13543776.2013.831071

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23967802